Lake Street Capital began coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report issued on Thursday, January 3rd, Marketbeat reports. The firm set a “buy” rating and a $14.00 price target on the stock. Lake Street Capital’s price objective would suggest a potential upside of 87.42% from the company’s previous close.
Other research analysts also recently issued reports about the company. Wedbush reissued a “buy” rating and issued a $30.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 14th. Royal Bank of Canada set a $24.00 target price on Aquestive Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Zacks Investment Research cut shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $24.25.
NASDAQ AQST opened at $7.47 on Thursday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42. Aquestive Therapeutics has a 1-year low of $5.80 and a 1-year high of $20.70.
Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15). The business had revenue of $13.27 million during the quarter, compared to the consensus estimate of $14.75 million. Analysts forecast that Aquestive Therapeutics will post -1.15 earnings per share for the current fiscal year.
In other news, CFO John T. Maxwell acquired 5,000 shares of the stock in a transaction that occurred on Thursday, December 6th. The stock was acquired at an average price of $8.87 per share, for a total transaction of $44,350.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO John T. Maxwell bought 10,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Wednesday, November 21st. The stock was bought at an average cost of $9.80 per share, with a total value of $98,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 28,650 shares of company stock valued at $275,311.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Keybank National Association OH acquired a new position in Aquestive Therapeutics in the 3rd quarter worth $239,000. Point72 Asset Management L.P. acquired a new position in Aquestive Therapeutics in the 3rd quarter worth $350,000. Citadel Advisors LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth about $451,000. Engineers Gate Manager LP acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth about $464,000. Finally, Brant Point Investment Management LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth about $622,000. 64.49% of the stock is owned by hedge funds and other institutional investors.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Featured Article: Momentum Investing
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.